HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATE
Falchi, L., Clausen, M. R., Offner, F., Vos, S., Brody, J., Linton, K. M., Snauwaert, S., Cordoba, R., Wu, J., Bykhovski, I., Wang, L., Rana, A., Belada, D.
Published in Hematological oncology (01.06.2023)
Published in Hematological oncology (01.06.2023)
Get full text
Journal Article
P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R‐DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
Cordoba, R., Falchi, L., Phillips, T., Vos, S., Nijland, M., Offner, F., Bykhovski, I., Wu, J., Wang, L., Rana, A., Abrisqueta, P.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article